Application and mechanism of dimethylfumarate in MS:research progress
10.7644/j.issn.1674-9960.2015.11.017
- VernacularTitle:富马酸二甲酯在多发性硬化中的应用及其机制研究进展
- Author:
Na LI
;
Jinliang LI
;
Renxi WANG
;
He XIAO
- Publication Type:Journal Article
- Keywords:
dimethylfumarate;
multiple sclerosis;
NF-E2 related factor 2;
T-lymphocytes
- From:
Military Medical Sciences
2015;(11):881-883
- CountryChina
- Language:Chinese
-
Abstract:
Multiple sclerosis(MS)is a demyelinating disease of the central nervous system and one of the most common autoimmune diseases,characterized by wide-spread lesions and relapsing-remitting encephalomyelitis,accompanied by optic nerve damage.Patients worldwide total about 2.5 million,mostly young adults and women.This disease remains incurable. Dimethylfumarate (DMF)is a new oral drug for MS,which was approved by the FDA in 2013 for clinical treatment of re-lapsing-remitting MS.It can reduce the activity of disease,and the relapsing-remitting MS relapse.This paper outlines the application of DMF to the treatment of MS and its mechanism of action.
